WO2009073167A3 - Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions - Google Patents
Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions Download PDFInfo
- Publication number
- WO2009073167A3 WO2009073167A3 PCT/US2008/013271 US2008013271W WO2009073167A3 WO 2009073167 A3 WO2009073167 A3 WO 2009073167A3 US 2008013271 W US2008013271 W US 2008013271W WO 2009073167 A3 WO2009073167 A3 WO 2009073167A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pulmonary fibrosis
- diagnosis
- compositions
- identification
- related methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Individuals with polymorphisms in MUC5AC are more likely to develop idiopathic interstitial pneumonia (IIP) or pulmonary fibrosis. This discovery provides methods to identify susceptible individuals, and also provides approaches to treatment in this life threatening disease that previously had no known beneficial therapy. Given the relatively high prevalence of some of these SNPs in the general population, it is likely that variants MUC5AC result in susceptibility to other fibroproliferative lung diseases, including asthma, chronic obstructive lung disease, granulomatous lung diseases, and pneumonconioses.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99207907P | 2007-12-03 | 2007-12-03 | |
US60/992,079 | 2007-12-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009073167A2 WO2009073167A2 (en) | 2009-06-11 |
WO2009073167A3 true WO2009073167A3 (en) | 2009-09-03 |
Family
ID=40718413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/013271 WO2009073167A2 (en) | 2007-12-03 | 2008-12-02 | Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009073167A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2787994C (en) | 2010-01-26 | 2021-01-12 | National Jewish Health | Diagnosis and prognosis of idiopathic interstitial pneumonia by rs35705950 snp in muc5b gene promoter |
WO2014197713A2 (en) * | 2013-06-05 | 2014-12-11 | The Regents Of The University Of Colorado, A Body Corporate | Molecular phenotyping of idiopathic interstitial pneumonia identifies two subtypes of idiopathic pulmonary fibrosis |
CN115322133B (en) * | 2022-07-29 | 2023-07-04 | 四川大学华西医院 | Application of compound in preparation of pulmonary fibrosis viscosity response fluorescent probe |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1403638A1 (en) * | 2002-09-25 | 2004-03-31 | Mondobiotech SA | Molecular methods for diagnosing interstitial lung diseases |
US20060275808A1 (en) * | 2005-05-20 | 2006-12-07 | Young Robert P | Methods of analysis of polymorphisms and uses thereof |
US20060292562A1 (en) * | 2002-05-29 | 2006-12-28 | Pollard Harvey B | Methods of identifying genomic and proteomic biomarkers for cystic fibrosis, arrays comprising the biomarkers and methods of using the arrays |
US20070099202A1 (en) * | 2005-05-19 | 2007-05-03 | Young Robert P | Methods and compositions for assessment of pulmonary function and disorders |
-
2008
- 2008-12-02 WO PCT/US2008/013271 patent/WO2009073167A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292562A1 (en) * | 2002-05-29 | 2006-12-28 | Pollard Harvey B | Methods of identifying genomic and proteomic biomarkers for cystic fibrosis, arrays comprising the biomarkers and methods of using the arrays |
EP1403638A1 (en) * | 2002-09-25 | 2004-03-31 | Mondobiotech SA | Molecular methods for diagnosing interstitial lung diseases |
US20070099202A1 (en) * | 2005-05-19 | 2007-05-03 | Young Robert P | Methods and compositions for assessment of pulmonary function and disorders |
US20060275808A1 (en) * | 2005-05-20 | 2006-12-07 | Young Robert P | Methods of analysis of polymorphisms and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2009073167A2 (en) | 2009-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005063819A3 (en) | Human binding molecule against cd1a | |
WO2009091994A3 (en) | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof | |
Vodicka et al. | Oxidative damage in sporadic colorectal cancer: molecular mapping of base excision repair glycosylases in colorectal cancer patients | |
WO2010018601A3 (en) | Genetic variants predictive of cancer risk | |
WO2006105252A3 (en) | Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells | |
WO2011020783A3 (en) | Targeted immunoconjugates | |
WO2009114532A3 (en) | Markers for diagnosis of pulmonary inflammation and methods related thereto | |
EP2639319A3 (en) | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof | |
JP2010516662A5 (en) | ||
WO2009059318A3 (en) | Genes and polymorphisms associated with amd | |
PL2390255T3 (en) | Novel aminoglycosides and uses thereof in the treatment of genetic disorders | |
NO20084488L (en) | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | |
WO2006096737A3 (en) | Diagnostic and therapeutic target for macular degeneration | |
WO2011106541A3 (en) | Diagnostic methods involving loss of heterozygosity | |
WO2006018632A3 (en) | Cell therapy with exo 1 | |
WO2007132292A3 (en) | Therapy for alzheimer's disease | |
WO2009073167A3 (en) | Identification and diagnosis of pulmonary fibrosis using mucin genes, and related methods and compositions | |
WO2006053245A3 (en) | Retroviral vectors with introns | |
WO2008088855A3 (en) | Gene polymorphisms as predictors of tumor progression and their use in cancer therapy | |
WO2008088876A3 (en) | Tissue factor promoter polymorphisms | |
WO2015067710A3 (en) | Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness | |
WO2007124157A3 (en) | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | |
WO2007071437A3 (en) | Compositions and methods for treating inflammatory disorders | |
Dunlap et al. | Characterizing the Lung Microbiome in a Well-Defined Chronic Bronchitis Cohort Undergoing Bronchial Rheoplasty | |
Dicker et al. | A21 CHRONIC AIRWAY INFLAMMATION: MICROBIAL INFLUENCE: Mannose Binding Lectin Deficient Haplotypes Are Associated With Fewer Exacerbations And A More Diverse Microbiome In Chronic Obstructive Pulmonary Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08857847 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08857847 Country of ref document: EP Kind code of ref document: A2 |